CM336 clinical trials
How each study uses CM336 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CM336 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2026 (7)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 9
Institute of Hematology & Blood Diseases Hospital, China (8) · Keymed Biosciences Co.Ltd (5) · Shandong First Medical University (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7, 1 in phase 3
Studies that test CM336, phase 3 first.
- Sep 2027Study of CM336 in Relapsed or Refractory Multiple Myeloma PatientsPhase 3 · Keymed Biosciences Co.Ltd
- Dec 2026BCMA/CD3 BsAb Therapy for POEMS SyndromePhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Jan 2027A Study to Evaluate CM336 in Adults With Autoimmune Bullous DiseasePhase 2 · Shandong First Medical University
- May 2027BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMMPhase 1 · Institute of Hematology & Blood Diseases Hospital, China
- Aug 2027Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic StratificationPhase 1/2 · Institute of Hematology & Blood Diseases Hospital, China
- Aug 2027BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple MyelomaNot applicable · Institute of Hematology & Blood Diseases Hospital, China
- Nov 2027A Study of CM336 in Patients With Relapsed or Refractory Autoimmune CytopeniaPhase 1/2 · Keymed Biosciences Co.Ltd
Studies
Open first, then newest update. How each study uses CM336 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple MyelomaNot yet recruitingPhase 3Keymed Biosciences Co.LtdNCT07910903Written as CM336
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07830485Written as CM336 (BCMA/CD3 bispecific antibody)
- A Study to Evaluate CM336 in Adults With Autoimmune Bullous DiseaseRecruitingPhase 2Shandong First Medical UniversityNCT06900010Written as CM336 Injection
- BCMA/CD3 BsAb Therapy for POEMS SyndromeRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07115654Written as CM336 (BCMA/CD3 bispecific antibody)
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07652905Written as CM336
- CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal ImpairmentRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07585760Written as CM336 Plus Isatuximab
- BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple MyelomaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06745687Written as CM336
- Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic StratificationNot yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07687004Written as CM336 (BCMA/CD3 bispecific antibody)
- CM336 for Active Sjogren's Syndrome StudyNot yet recruitingPhase 1Keymed Biosciences Co.LtdNCT07642843Written as CM336
- BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMMNot yet recruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT07407010Written as CM336 (BCMA/CD3 bispecific antibody)
- A Study of CM336 in Patients With Relapsed or Refractory Autoimmune CytopeniaRecruitingPhase 1/2Keymed Biosciences Co.LtdNCT07175493Written as CM336 Injection
- Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain AmyloidosisRecruitingPhase 2Keymed Biosciences Co.LtdNCT07039578Written as CM336 Injection(Low dose group)
- Study of CM336 in Relapsed or Refractory Multiple Myeloma PatientsNot yet recruitingPhase 3Keymed Biosciences Co.LtdNCT07181239Written as CM336 Injection
- An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune ThrombocytopeniaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06799611Written as CM336 Injection
What changed recently
From the registry's own updates since Oct 17, 2026.